PCSK9 and systemic lupus erythematosus: Our drug-target MR study showed that inhibition of the PCSK9 gene was causally associated with a lower risk of SLE in the European population, but this association was not confirmed in the East Asian population, suggesting the diversity in the causal effect of PCSK9 inhibition on SLE risk in different populations.